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Available online 16 March 2016The development of oncoprotein-targeted anticancer drugs is an invaluable weapon in the war against cancer.
However, cancers do not give up without a ﬁght. They may develop multiple mechanisms of drug resistance, in-
cluding apoptosis inhibition, drug expulsion, and increased proliferation that reduce the effectiveness of the drug.
The collective work of researchers has highlighted the role of cytokines in the mechanisms of cancer drug resis-
tance, as well as in cancer cell progression. Furthermore, recent studies have described how speciﬁc cytokines se-
creted by cancer stromal cells confer resistance to chemotherapeutic treatments. In order to gain a better
understanding of mechanism of cancer drug resistance and a prediction of treatment outcome, it is imperative
that correlations are established between global cytokine proﬁles and cancer drug resistance. Here we discuss
the recent discoveries in this ﬁeld of research and discuss their implications for the future development of effec-
tive anti-cancer medicines.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Cytokine
Cancer drug resistance
Stromal cells
Tumor microenvironment
Antibody array
Multiplex immunoassayContents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256
2. Cytokine perturbations in cancer development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257
3. Cancer cells secrete cytokines to evade drug-induced death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257
4. Cytokines secreted from stromal cells contribute to cancer drug resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260
5. Cytokines can be predictive biomarkers in cancer drug treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261
6. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 262
Statement of conﬂict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 263otility factor; AML, acutemyeloid leukemia; BCL, B-cell lymphoma; BCR, breakpoint cluster region; BM, bonemarrow; CCL, che-
a; ECM, extracellularmatrix; EGF, epidermal growth factor; EMT, epithelial–mesenchymal transition; FGF, ﬁbroblast growth fac-
mcitabinemonotherapy; HER2, human epidermal growth factor receptor 2; HGF, hepatocyte growth factor; IL, interleukin;Mcl-
MP, matrix metalloproteinase; MRCC, metastatic renal cell carcinoma; NGAL, neutrophil gelatinase-associated lipocalin; PARP,
l; PI3, phosphoinositide 3; PSCs, pancreatic stellate cells; RANTES, regulated on activation, normal T cell expressed and secreted;
cer and activator of transcription 3; TGF, transforming growth factor; TKI, tyrosine kinase inhibitor; TNF, tumor necrosis factor;
ay Lane, Norcross, GA 30092, USA.
uang) made equal contribution to this paper and are considered co-ﬁrst authors.
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
256 V.S. Jones et al. / Biochimica et Biophysica Acta 1865 (2016) 255–2651. Introduction
The development of effective treatments against cancer has been an
ongoing biomedical endeavor over the past 50 years [1,2]. Many treat-
ments involve the use of cytotoxic chemotherapy agents that have pow-
erful anti-cancer activities. Despite the effectiveness of these agents
against tumors, most chemotherapy protocols do not effectively
increase patient survival. However, decades of research have brought
us a deeper understanding of the molecular basis of many cancers, en-
abling newer,more advanced strategies for tumor killing. The recent de-
velopment of oncoprotein-targeted drugs, a breakthrough weapon in
the war on cancer, uses precise inhibitors and antibodies to block path-
ways or targets that are speciﬁc to the tumor. Tremendous progress in
cancer treatment has emerged from this latest generation of drugs,
most notably the kinase inhibitors targeting the V600E-B-RAFmutation
in late stage melanoma, the BCR-ABL fusion protein in chronic myeloid
leukemia (CML), and the EML4-ALK translocation in non-small cell lung
cancer (NSCLC) [3]. However, even after a profound initial response to
the targeted therapy, the majority of cancers acquire resistance to
these agents and begin to grow again. Thus, despite the improvement
in patient survival rates and reduction of side effects, relapse remains
our primary challenge [4].
The resistance to cytotoxic or targeted chemotherapy drugs may be
present before cancer therapy, or may arise as a result of cancer therapy.
In some cases, theremaybe only subpopulations of cellswithin the tumor
that possess resistance mechanisms, thus resulting in their competitive
expansion following drug administration. As the tumor develops, muta-
tions may then occur in some cells, resulting in those possessing the
most efﬁcient improvements to proliferate, conferring a selective advan-
tage. Moreover, as cells within the tumor acquire somatic mutations,
the genetic proﬁle of the tumor becomes heterogeneous, wherein differ-
ent populations of cells acquire dissimilar genetic ﬁngerprints. [5]. Inten-
sifying this problem are observations of multidrug resistance (MDR),
meaning that more complex strategies of chemotherapy must be devel-
oped to overcome resistance. Thus, the development of the next genera-
tion of cancer therapies must occur with resistance mechanisms as
hindsight, and in this review, we attempt to summarize the key drug re-
sistance pathways which represent putative therapeutic strategies.
Chemotherapy drug resistance may originate from various mecha-
nisms including dysregulated apoptosis, somatic mutations within
drug targets, or modiﬁcation of drug metabolism and transport. Resis-
tance may be a pre-existing, innate feature of the cancer cell (intrinsic
drug resistance), ormay be acquired during the course of treatment (ac-
quired resistance) as tumors adapt to and counter drug exposure. Both
scenarios typically lead to a relapse following therapy. There are two
major mechanisms, both not mutually exclusive, that may account for
intrinsic or acquired resistance of tumors against chemotherapeutic
drugs. The ﬁrst is simply a failure of plasma membrane receptors on
tumor cells to actively take up anti-cancer agents. The second mecha-
nism involves drug elimination through the ejection of cytostatic sub-
stances across the cell membrane. This phenomenon is responsible for
manymultidrug resistance (MDR) phenotypes, and is amajor inﬂuence
in the failure of chemotherapy strategies [5,6]. On the other hand, ac-
quired resistance develops following continuous exposure to drugs
that induce genetic and/or epigenetic changes eventuating in
proapoptotic pathway blockade, and/or constitutive expression of
anti-apoptotic proteins [7,8] as well as increased efﬁciencies in cellular
DNA damage repair mechanisms [9].
However, the combination of all the mechanisms described above
does not fully explain chemotherapy drug resistance, indicating that un-
known cancer drug resistance mechanisms remain to be discovered.
With the expanding arsenal of anticancer agents and the introduction
of comprehensive high-throughput screening, there are now prospects
of overcoming drug resistance through the clinical assessment and stra-
tegic implementation of drug combinations, and through the identiﬁca-
tion of predictive biomarkers.Recent studies have implicated dysregulated cytokine expression
as a crucial aspect of many drug resistance mechanisms [4,5,10]. Cy-
tokines, which we broadly deﬁne here as a diverse category of se-
creted molecules which includes chemokines, growth factors, pro-
and antiangiogenic factors, adipokines, soluble receptors and extra-
cellular proteases, play pivotal roles in both normal and pathologic
cellular events. The proliferation of tumor cells and the formation
of stromal blood vessel networks, both of which support progressive
tumor growth, are directed by aberrant cytokine signaling. Cytokines
are responsible for a number of physiologic processes that are
strongly correlated with tumorigenesis, tumor development and
metastasis; these processes include inﬂammation [11], cell migra-
tion [12], angiogenesis [13], and apoptosis [14]. Additionally, evi-
dence is emerging that the cytokines secreted by cancer cells and
their associated stroma play a key role in a number of drug resistance
mechanisms [15,16]. Although our understanding of how cytokines
inﬂuence drug resistance is currently sparse, it has become clear
that cytokines represent legitimate therapeutic targets and bio-
markers, and further exploration of their function in these contexts
is urgently needed.
It is likely that early diagnosis of cancer drug resistance may
eventually be accomplished bymonitoring changes in circulating cy-
tokine levels during chemotherapy. This would allow investigators
to evaluate tumor response to a particular drug, and glean guidance
in the application of alternative chemotherapeutic strategies. Fortu-
nately, cytokine levels can be easily measured in serum or plasma,
ﬂuids that are collected by minimally invasive methods. However,
an obstacle to this approach is the realization that alteration in the
levels of a single cytokine rarely constitutes an accurate biomarker,
and that the true pathology of the disease state is understood fully
by measuring multiple cytokines in parallel [17]. This broader per-
spective of cytokine expression requires high content, high-
throughput methodologies for measuring protein levels in blood.
To address this need, a number of platforms have been introduced
within the last 20 years that employ the simultaneous use of multi-
ple antibodies to expand the efﬁciency of protein detection in small
sample volumes. These platforms have a promising track record of
being successfully utilized in the discovery of biomarkers and key
drug resistance-related molecules. For example, the multiplex im-
munoassay, an ELISA-based technique utilizingmany antibodies reg-
ularly arranged on a solid support, enables efﬁcient cytokine
expression proﬁling from low volume biospecimens. This approach
has contributed signiﬁcantly to our understanding of cytokine dy-
namics in the tumor microenvironment [18] and has greatly acceler-
ated biomarker discovery [19,20].
Multiplex immunoassays are proteomic techniques that are used for
the detection of panels of key proteins involved in disease states. They
exist on two major platforms: 1) antibody arrays (antibodies spotted
onto planar solid supports such as glass slides,membranes, ormicrotiter
plates) and 2) bead-based assays (antibodies coupled to ﬂuorescent-
labeled microbeads). Both techniques are technically straightforward
andmay be used to detect protein expression proﬁles from diverse bio-
logical ﬂuids. Moreover, multiplex immunoassays have proven crucial
in instances of biomarker detection for many diseases including immu-
nologic disorders, asthma, neurological dysfunction, renal disease, and
others [17].
Herein, we review recent advancements in the identiﬁcation of
novel drug resistance mechanisms, in which drug resistance is con-
ferred by speciﬁc cytokines secreted by the cancer cells. In addition,
we highlight the contribution of stromal cells within the tumor, and
how their secretion proﬁles contribute to cancer drug resistance. We
also discuss the utility of multiplex immunoassay platforms as predic-
tivemethods in determining cancer drug efﬁcacy, and present examples
of how researchers employed antibody-based screens to assess the ex-
tent towhich cytokines function as effectormolecules in cancer drug re-
sistance mechanisms.
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Cytokines that directly inﬂuence cancer progression include a varie-
ty of angiogenic growth factors that regulate cancer cell proliferation
and the formation of vessel networks within tumors. For example, vas-
cular endothelial growth factor (VEGF), a highly potent proangiogenic
factor, is highly expressed within most tumors, where it stimulates
the migration and proliferation of endothelial cells and formation of
blood vessels [21,22]. In addition, malignant transformation is often as-
sociatedwith aberrant expression ofﬁbroblast growth factor (FGF), epi-
dermal growth factor (EGF) and hepatocyte growth factor (HGF), all of
which stimulate proliferation of tumor and stromal cells and manifest
potent angiogenic effects [23–26]. Transforming growth factor beta
(TGF-beta), a highly pleiotropic growth factor with complex and para-
doxical implications for cancer, has been found to exhibit both pro and
anti-tumorigenic effects, depending on the context. In some instances
TGF-beta suppresses growth or activates apoptosis, inhibiting cancer
progression. In other instances, it promotes cancer through the induc-
tion of epithelial–mesenchymal cell transition (EMT), which can induce
cancer cells to de-differentiate and acquire cancer stem-cell-like prop-
erties [27]. Tumor cells are known to acquire aberrant responses to
TGF-beta and matrix metalloproteinases (MMPs), which can induce
speciﬁc EMT programs [28,29].
Tumor cells also produce cytokines and chemokines such as
interleukin-6 (IL-6), IL-8, IL-10, monocyte chemoattractant protein 1
(MCP-1), and regulated on activation, normal T cell expressed and se-
creted (RANTES) all of which have complex autocrine and paracrine ef-
fects. IL-6 is a pleiotropic pro-inﬂammatory cytokine that promotes B-
and T-cell differentiation, induces acute phase reactant production,
and stimulates hematopoiesis. IL-6 has been demonstrated to directly
stimulate proliferation of tumor cells and promote angiogenesis
[30–32]. Several reports have found that IL-6 levels correlate with dis-
ease progression and inversely correlate with response to treatment
and survival [33]. IL-8 belongs to the superfamily of CXC chemokines
and has a wide range of pro-inﬂammatory effects. It stimulates migra-
tion of neutrophils, monocytes, and lymphocytes, and promotes tumor
cell proliferation and metastasis [34–36]. In addition, IL-8 exhibits
strong angiogenic activity [34,35,37]. Chemokines of the CC superfamily
such as RANTES and MCP-1 also are able to stimulate migration of nor-
mal and malignant cells, as well as promote tumor angiogenesis
[38–40]. IL-10, a potent immunosuppressive cytokine which is fre-
quently overexpressed in tumors, plays an important role in protecting
cancer cells from immune-mediated destruction [41]. Collectively, this
nexus of secreted signals serves to drive tumor progression and subvert
cell function by potentiating the key hallmarks of cancer, such as chron-
ic proliferation, perturbation of immunosurveillance, recruitment of
blood vessels, and avoidance of apoptosis.
In addition, these aberrant cytokine signals eventuate in other ef-
fects which are nowwidely recognized to be crucial for cancer progres-
sion, i.e., reprogramming the tumor microenvironment (TME) to
facilitate tumor growth. Speciﬁcally, tumor cells hijack local non-
malignant cell types (tumor-associated stromal cells), directing them
to actively serve the tumor's agenda. These non-malignant stromal
cells, which include endothelial cells, ﬁbroblasts, lymphocytes, and
macrophages, can be re-educated to supply a speciﬁc cocktail of cyto-
kines, chemokines, growth and angiogenic factors to the tumor,
inﬂuencing the survival and proliferation of tumor cells. Thus, there ex-
ists a continuous cross-talk between tumor and stromal cells, where
generated soluble factors represent a tumor cytokine network that
plays an essential role in tumor growth and protection from endoge-
nous (hypoxia, oxygen free radicals) and exogenous (chemotherapy
drugs, ionizing radiation) damage. Overproduction of these factors by
growing tumors has been shown to lead to the increases in circulating
levels of cytokines, chemokines, angiogenic and growth factors which
are often associatedwith resistance to therapy and overall poor progno-
sis [33,34,42–44]. We will now describe speciﬁc examples of seminaldiscoveries in the ﬁeld that signiﬁcantly advanced our understanding
of the function of cytokines in cancer drug resistance.3. Cancer cells secrete cytokines to evade drug-induced death
One of the more extensively characterized mechanisms of drug ef-
ﬂux from cancer cells is attributable to dysregulation of the mdr1
gene, which results in abnormally high expression of the protein
MDR1, also known as P-glycoprotein (P-gp). Belonging to the ATP-
binding cassette (ABC) family of transporter proteins, P-gp is a trans-
membrane pump which serves to eliminate a variety of toxic com-
pounds, including major cancer chemotherapeutics [5]. Expression of
P-gp can in some instances be upregulated by cytokines [45,46]. P-gp-
mediated MDR involves signaling through several signal pathways
and transcription factors, including the ERK, JNK, p38, PI3-kinase and
protein kinase C signaling pathways. Thus, drugs targeted against
these pathways may provide new therapies for treatment of ABCB1/
Pgp-mediated MDR [47].
Since the 1990s, it has been repeatedly observed that breast cancer
patients with elevated serum levels of IL-6 exhibited poorer prognosis
[48,49]. Studies into the mechanistic role of IL-6 in breast cancer pro-
gression revealed that the drug-sensitive breast cancer cell line MCF-7
does not express IL-6, whereas high levels of IL-6 are produced by
multidrug-resistant sublines. Itwas further observed that both pretreat-
ment with exogenous IL-6 and constitutive expression of IL-6 rendered
drug-sensitive breast cancer cells resistant to several chemotherapy
agents (doxorubicin, vincristine, and taxol). This protectionwas accom-
panied by the activation of the CCAAT enhancer-binding protein (C/
EBP) family of transcription factors, and mdr1 gene expression. This
study revealed that breast cancer cells could acquire the ability to ex-
press IL-6, which confers autocrine cellular multi-drug resistance, and
thus represents a self-protective mechanism [50]. This ﬁnding is espe-
cially signiﬁcant in light of previous Phase I/II clinical trials in which
IL-6 had been administered to breast and lung cancer patients in combi-
nation with chemotherapy for its ability to stimulate platelet growth
[51].
Several groups have observed that an autocrine IL-6 loop contributes
substantially to drug resistance of prostate cancer. LNCaP-IL6+ cells,
which are a model system for therapy-resistant prostate cancer, were
found to express increased levels of Mcl-1 protein, an anti-apoptotic
member of the Bcl-2 family. Treatment of cells with a chimeric anti-IL-
6 antibody led to the induction of apoptosis and the down regulation
of Mcl-1 protein levels [52]. Moreover, some prostate cancer cell lines
are resistant to enzalutamide (an androgen antagonist) by amechanism
thought to be due to autocrine IL-6-induced constitutive activation of
signal transducer and activator of transcription 3 (STAT3) and its target
genes. Indeed, inhibition of STAT3 expression or addition of the STAT3
inhibitor AG490, led to increased sensitivity of prostate cancer cells to
enzalutamide. This study implies that targeting the IL-6-STAT3 axis
along with enzalutamide treatment may be a viable therapeutic strate-
gy for patients with enzalutamide resistant prostate cancer. [53].
To identify molecular changes involved in MDR, the cytokine proﬁle
of a multidrug-resistant human breast cancer cell line MCF-7/R was
assessed using a cytokine antibody array that simultaneously detects
120 target proteins [54]. From this screen, expression of both IL-6 and
IL-8 were found to be signiﬁcantly increased compared to the sensitive
parent cell line (MCF-7/S) and neutralizing antibody assays indicated
that MDRwas dependent on the activities of IL-6 and IL-8. An indepen-
dent study also observed high levels of IL-6 and IL-8 in an antibody array
experiment investigating drug resistance to the gamma-secretase in-
hibitor RO4929097 (an inhibitor of the Notch signaling axis). Here, xe-
nograft models indicated that resistance to RO4929097 was associated
with increased tumor cell-derived IL-6 and IL-8 expression levels [55].
Collectively, these ﬁndings suggest that IL-6 and IL-8 are key markers
for the development of resistance to several drug types.
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array of cellular defense responses such as the induction of anti-
apoptotic factors and the production of pro-inﬂammatory and pro-
angiogenic cytokines such as IL-6 and IL-8. NF-kappa B signaling occurs
in response to a broad range of external stimuli, including bacteria, vi-
ruses, pro-inﬂammatory cytokines, ionizing radiation, and genotoxic
substances. Of importance to cytokines and cancer drug resistance is
the fact that NF-kappa B is activated by a number of cytotoxic chemo-
therapy agents including cisplatin, paclitaxel, docetaxel, and doxorubi-
cin [56,57]. Unfortunately, this response commonly eventuates in
drug-resistant tumors due to the upregulation of pro-survival cell sig-
naling pathways. This, combinedwith the fact thatmany cancers are in-
herently characterized by dysregulation or constitutive activation of NF-
kappa B, has stimulated a great deal of interest in therapeutics targeting
various aspects of NF-kappaB signaling [58,59]. For example, onepartic-
ularly effective compound, bortezomib (trade name Velcade), can sup-
press NF-kappa B-dependent gene expression, including cytokine
production, through inhibition of the 26S proteasome. Inhibition of
the 26S subunit has the effect of blocking the degradation of the Inhib-
itor of kappa B (I-kappa B), which keeps NF-kappa B in check,
preventing its translocation to the nucleus. The net effect of bortezomib
is blockade of NF-kappa B-dependent gene transcription. [60,61]. While
bortezomib has proven effective against multiple myeloma, it is less ef-
fective for certain solid tumors and can in some instances, paradoxically
activate NF-kappa B [62,63]. Furthermore, in ovarian and prostate can-
cer cells, bortezomib treatment has been shown to stimulate the secre-
tion of IL-8. This upregulation proceeds through the direct
phosphorylation and accumulation of the p65 subunit of NF-kappa B
within the nucleus. Here, phospho-p65 is recruited to the IL-8 promoter
alongwith EGR-1 (early growth response-1), and the inhibitor of kappa
B kinase beta (IKK-beta) [64]. Given that ovarian cancer progression has
been associated with elevated expression of IL-8 and other proinﬂam-
matory cytokines, this ﬁnding may explain the failure of bortezomib
as an effective treatment for ovarian cancer.
Other cytokines contributing to anti-cancer drug resistance were
discovered in the human ﬁbrosarcoma cells. The HT 1080 cell line se-
creted high levels of AMF (autocrinemotility factor) andwere also resis-
tant tomitomycine C (MMC)-induced apoptosis. Analysis indicated that
AMF abrogated expression of Apaf-1 and caspase-9, which are essential
for the progression of intrinsic apoptosis. Corroborating these ﬁndings,
treatment with antibodies against AMF induced apoptosis in vitro and
effectively aidedMMC-induced apoptosis in vivo [65], altogether show-
ing that AMF expression represents an important protectivemechanism
in the in vitro cultured human ﬁbrosarcoma HT-1080 line.
Another secreted molecule which has recently emerged as a poten-
tial marker of drug resistance is adrenomedullin (AM), a 52-amino acid
vasodilatory peptide. AM is expressed and secreted in both normal and
malignant prostate cells, where it acts in an autocrine fashion. Under the
anti-cancer drug etoposide, AM inhibited apoptosis in PC-3 and LNCaP
prostate carcinoma cells. Constitutive expression of AM in PC-3 cells
lowered basal levels of phosphorylated ERK1/2, which was unaffected
following etoposide treatment. In addition, etoposide-induced apopto-
sis in PC-3 cells was signiﬁcantly inhibited following constitutive AM
expression, demonstrating that AM plays a critical role in preventing
etoposide-induced apoptosis of prostate cancer cells. [66,67].
Based on observations that T-helper lymphocyte-derived cytokines
could mediate autoimmune thyroid destruction, one group focused in-
vestigations on the autocrine activities of the Th2/Th3 cytokines IL-4
and IL-10 in modulating thyroid cancer resistance to cytotoxic chemo-
therapy agents. This group observed upregulation of the anti-
apoptotic factors Bcl-2 and Bcl-xL in thyroid carcinoma cells which
were refractory to cisplatin, doxorubicin or taxol. IL-4 and IL-10 secre-
tion was associated with increased levels of Bcl-2 and Bcl-xL, thus
protecting thyroid cells from chemotherapeutic agents. Furthermore,
neutralization of IL-4 and IL-10 promoted thyroid cancer cell apoptosis
and dramatically increased the effect of chemotherapy drugs. Thesedata suggest that both chemokines have potent modulating inﬂuences
on tumor cell survival [68].
The epidermal growth factor receptor (EGFR) tyrosine kinase inhib-
itor (TKI) erlotinib causes feedback activation of STAT3 signaling in PC-9
cells, a non-small-cell lung carcinoma (NSCLC) line harboring EGFR-
activating mutations. Intriguingly, the conditioned medium from
erlotinib-treated PC-9 cells signiﬁcantly increased erlotinib resistance
when applied to naïve PC-9 cells. To identify the secreted factors that
contribute to this induced drug resistance, a large antibody array-
based screen of the culture medium was conducted. The array revealed
that IL-6, IL-1 alpha and galectin were highly expressed, resulting in ac-
tivation of STAT3 and its target IRF-1. Importantly, STAT3 knockdown
efﬁciently prevented PC-9 from developing erlotinib resistance, which
was thought to be due to STAT3 activation through IL-6/Janus kinase 1
(JAK1) signaling. Given that cytokine-induced STAT3 feedback activa-
tion is associated with poor prognosis in lung adenocarcinoma, this
ﬁnding provides rationale for combination therapies that disrupt this
feedback mechanism [69]. In agreement with this ﬁnding, the impor-
tance of STAT3 signaling in chemotherapeutic drug resistance was also
demonstrated in a tamoxifen-resistant MCF-7 (TRM-7) cell model.
TRM-7 culturemediumwas shown to strongly induce STAT3 phosphor-
ylation in parental MCF-7 cells. Subsequently, a cytokine antibody array
analysis revealed increased levels of RANTES in TRM-7 culture medium.
This ﬁnding was validated by the addition of a neutralizing antibody to
RANTES, which blocked STAT3 activation and lowered the resistance of
TRM-7 cells to tamoxifen (Fig. 1). Thus STAT3-RANTES autocrine signal-
ing is essential for tamoxifen resistance in human breast cancer cells
[70].
There is evidence to suggest that, within a population of tumor cells,
minority clones of intrinsically drug-resistant cells actually beneﬁt from
targeted drug therapy, allowing the tumor to progress faster. A recent
study examined the mechanisms by which heterogeneous tumor cell
populations evolve and adapt to therapeutic stress [71]. Rather than fo-
cusing on a few pre-selected proteins or pathways, a broader approach
was taken. Transcriptomic and antibody array analysis of melanoma
cells revealed that drug-sensitive cells stressed by vemurafenib (a B-
RAF inhibitor) produce a complex secretome which not only promotes
their survival, but hastens the growth and dissemination of neighboring
vemurafenib-resistant cells. This therapy-induced secretome included
many upregulated cytokines which resulted in hyperactivated PI3-
kinase/Akt signaling. Since this ﬁnding predicted a possible route of
combination therapy, cells were co-treated with vemurafenib and ei-
ther MK2206 (Akt inhibitor) or BEZ235 (PI3-kinase/mTOR inhibitor).
Indeed, the outgrowth of resistant cells was blunted under both of
these conditions, diminishing the beneﬁts of the therapy-induced
secretome [71]. Thus, even as a tumor regresses in response to therapy,
its microenvironment becomes infused with a variety of tumor-
promoting signaling cues. Fortunately, the emerging population of re-
sistant cells appears to be vulnerable to inhibition of the alternate path-
ways it activates.
Intrinsic or acquired resistance to targeted therapies may proceed
through expression of growth factors that bind to alternate receptors
and activate downstream survival pathways (thus bypassing the drug
target entirely). Evidence of this type of adaptive signaling was demon-
strated when HGF, a ligand of the hepatocyte growth factor receptor
(HGFR, otherwise known as MET), was shown to induce geﬁtinib resis-
tance in lung cancer cells with EGFR-activating mutations. Resistant
cells were demonstrated to have restored PI3-kinase/Akt signaling via
phosphorylation of the receptor MET, and that this activation occurred
independently of EGFR. Reversal of geﬁtinib resistance by an anti-HGF
antibody in vitro suggested that speciﬁc inhibition of the HGF/MET
axis may be a viable therapeutic strategy to overcome TKI resistance
[72]. In agreement with this rationale, later studies found that, in vitro
and in vivo, small preexisting populations of lung adenocarcinoma
cells exhibit MET ampliﬁcation (and thus drug resistance) prior to TKI
treatment. Furthermore, treatment with the EGFR kinase inhibitor
Fig. 1.Acquisition of tamoxifen resistance inMCF-7. The RANTES autocrine loop activates STAT3 pathway signalingwhich in turn, promotes RANTES secretion and inhibits caspase-9/PARP
activity via the modulation of BCL-2/BCL-xL activity. Tamoxifen suppresses tumor cells by inducing apoptosis and caspase-9/PARP inactivation, thus sensitizing cells to chemotherapy
drugs.
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ate the development ofMET ampliﬁcation, resulting in clonal expansion
of these rare, TKI-resistant cells. Thus, speciﬁc mechanisms of acquired
drug resistance may be predetermined. Importantly, the combination
of MET inhibitor and TKI effectively reversed drug resistance. These
ﬁndings suggest that treatment-naïve lung cancer patients harboring
EGFR andMETmutations may beneﬁt from initial combination therapy
to block development of drug resistance [73].
In breast carcinomas, human epidermal growth factor receptor 2
(HER2) is highly expressed in 15–20% of cases. Trastuzumab (also
known as Herclon or Herceptin), a monoclonal antibody that targets
the HER2 receptor, is widely used to improve the prognosis of patients
with HER2-positive breast cancer. However, a signiﬁcant portion ofFig. 2. Tumor cells evade drug inhibition by autocrine regulation. Cytokines secreted by tumor c
thus countering the chemotherapy drug effect. Some activated pathways upregulate expressio
cytoplasmic drug concentration and contributing to the development of drug resistance.HER2-positive breast cancer patients eventually develops trastuzumab
resistance. Putative ligands of HER2 have been previously investigated
[74] but no ligand binding directly to HER2 has been identiﬁed. HER2
shares common signaling pathways and forms a heterodimer with
EGFR [75]. Amphiregulin is one of the ligands of EGFR and plays a prom-
inent role inmammary gland development aswell as tumorigenesis. In-
vestigations into the clinical relevance of circulating amphiregulin on
trastuzumab therapy in HER2-positive breast cancer patients revealed
that high serum amphiregulin levels were associated with early disease
progression, possibly due to Akt and ERK signaling activation by
amphiregulin [76]. This observation represents a mechanism of
cytokine-mediated drug resistance which involves activation of down-
stream signaling pathways common to the cognate receptor and theells activate a variety of signal pathways that are involved in cell survival and proliferation,
n of membrane proteins that function to expel drugs from the cytoplasm, thus reducing
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plicates amphiregulin as a putative biomarker for resistance to ﬁrst-line
trastuzumab-based therapy in HER2-positive breast cancer patients.
4. Cytokines secreted from stromal cells contribute to cancer drug
resistance
The TME plays an integral and increasingly appreciated role in tu-
morigenesis and cancer progression [77–79]. The resident cell types
within the TME are varied and include numerous bonemarrow-derived
cell types (neutrophils, macrophages, mast cells, and others), endothe-
lial cells of blood or lymphatic origin, pericytes, cancer-associated ﬁbro-
blasts (CAFs), and mesenchymal stem cells. These non-malignant cells
and the soluble factors they secrete can inﬂuence cancer cell growth
and metastasis in diverse ways, for example by increasing cell survival,
enabling invasiveness, and modulating drug response (Fig. 2). Immune
cells may promote cancer initiation by secreting cytokines and growth
factors which stimulate epithelial proliferation and generate reactive
oxygen species, which can culminate in DNA damage [80,81]. In re-
sponse to overproduction of VEGF, endothelial cells proliferate and
form pathological vasculatures. Pericytes, which are recruited to the
tumor by platelet-derived growth factor-beta (PDGF beta) gradients
[82], take up residence on the exterior of blood vessels, where they
are thought to play a role in immunosuppression. Fibroblasts, the pre-
dominant non-immune stromal cell type in the TME, not only synthe-
size and remodel the extracellular matrix (ECM) of the tumor stroma,
but also support cancer cell growth by paracrine secretion of growth
factors (Fig. 3).
While the role of the TME in cancer initiation, growth, and metasta-
sis has been extensively studied, its role in chemotherapy drug resis-
tance has only been partially described. Our sparse understanding of
stroma-mediated drug resistance mechanisms is a major impediment
to successful cancer treatment due to a lack of target molecules upon
which to focus therapies. The contributions of the TME and its constitu-
ent stromal cell populations to targeted drug resistance are beginning to
be appreciated; in fact, one study employed antibody arrays to probe
stromal secretomes in order to begin to answer this question. Therein,
it was discovered that tumor stroma can directly elicit innate resistance
to RAF inhibitors through HGF secretion [83]. Using a co-culture system,
23 different stromal cell types were surveyed for their capacity toFig. 3. The paracrinemodel of cancer drug resistance. The tumormicroenvironment plays a cruc
act in a paracrine fashion, activating signaling pathways within tumor cells that contribute to dr
drug elimination.generate innate resistance in 45 cancer cell lines to 35 different antican-
cer drugs (both cytotoxic and oncoprotein-targeted agents). From this
multitude of data, it was found that stroma-mediated resistance oc-
curred frequently, particularly with the targeted drugs. Furthermore,
this resistancewas recapitulated by stromal cell medium alone, indicat-
ing a soluble secreted factor was responsible. Antibody array analysis of
themedium revealed that HGFwas expressed highly, and this resulted in
downstream activation of MAPK and PI3-kinase/Akt signaling through
MET, which conferred immediate resistance to the RAF inhibitor
PLX4720 [83]. As with other studies that employ a dual inhibition strate-
gy, the disruption of both HGF and MET function resulted in reversal of
drug resistance, again showing that combination targeted therapy is a po-
tential therapeutic strategy for melanoma, and exemplifying a powerful
method of uncovering mechanisms underlying drug resistance.
Pancreatic cancer has thepoorest prognosis of all the cancers and ex-
hibits a high degree of resistance to available chemotherapeutic agents.
The contribution of pancreatic stellate cells (PSCs) has been shown to be
critical for pancreatic cancer progression [84] and potentially critical for
chemoresistance [85,86]. Recently, a study probed the mechanism of
PSC-mediated pancreatic cancer chemoresistance, speciﬁcally querying
the contribution of SDF-1 alpha/CXCR4 signaling based on its critical
role in a variety of other epithelial cancers [87–90]. It was demonstrated
that primary PSCs expressed SDF-1 alpha, while its receptor CXCR4was
highly expressed in pancreatic cancer cells (PCCs). The culture media
from PSCs repressed gemcitabine-induced cytotoxicity and apoptosis
in PCCs; this effect was antagonized by an SDF-1 alpha neutralizing an-
tibody and recapitulated with recombinant SDF-1 alpha treatment. Ad-
ditionally, recombinant SDF-1 alpha increased IL-6 expression in PCCs in
a CXCR4-dependent fashion, and increased focal adhesion kinase (FAK),
ERK1/2, Akt and p38 phosphorylation. Taken together, these data dem-
onstrated that PSCs can confer chemoresistance to PCCs via paracrine
SDF-1 alpha/CXCR4-mediated activation of intracellular FAK-Akt and
ERK1/2, with a subsequent IL-6 autocrine loop [91].
The bonemarrow (BM) is composed of both hematopoietic cells and
nonhematopoietic cells which include BM stromal cells, endothelial
cells, osteoclasts, and osteoblasts. These cell types and the soluble
factors which they secrete including cytokines, growth factors, and
chemokines, along with the ECM, constitute the entire BM microenvi-
ronment [92]. The BMmicroenvironment plays an important role in dif-
ferentiation, migration, proliferation, survival, and drug resistance ofial role in drug resistance. Stromal cells and tumor-associated cells secrete cytokineswhich
ug resistance. Mechanisms include apoptosis inhibition, proliferation, and active transport
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tive therapy for treatment of chronic myeloid leukemia (CML), inhibits
theBCR-ABL kinase oncogene in CML cells. However, the BM is known to
confer imatinib resistance in K562 cells by secreting BM stroma-derived
soluble factors that increase STAT3 phosphorylation (tyrosine 705) and
subsequently increase the expression of anti-apoptotic proteins. [93].
Additionally, treatment with ABL TKIs cures only a minority of CML pa-
tients due to the activation of survival signals in CML stem/progenitor
cells (SPCs) through pathways such as JAK2/STAT5 [94]. However, it
has been reported that combination treatment of the JAK1/2 inhibitor
ruxolitinib with the tyrosine kinase inhibitor nilotinib, reduced the ac-
tivity of the JAK2/STAT5 pathway and contributed to the elimination
of CML CD34+ cells in vitro and in vivo. Thus, the JAK2/STAT5 pathway
is a relevant therapeutic target for eradication of persistent disease in
CML patients [95].
Acute myeloid leukemia (AML) is a malignant and aggressive dis-
ease which is insensitive to chemotherapy. The dynamic interaction be-
tween AML cells and BM microenvironment plays a critical role in the
response of this disease to chemotherapy [96]. For example, imatinib
and nilotinib (both inhibitors of c-KIT/ABL) have been shown to block
proliferation of two c-KIT mutant AML cell lines, an effect which was
signiﬁcantly diminished when the cells were cultured in conditioned
medium from BM stromal cells (either HS-5 or primary BM stromal
cells). After testing the ability of several cytokines to rescue AML cell
lines from c-KIT induced apoptosis, itwas found that granulocyte colony
stimulating factor (G-CSF) treatment could mimic the effects observed
with HS-5 conditionedmedium [97]. Thus, a clear role was demonstrat-
ed for G-CSF in modulating the response of AML cells to c-KIT inhibition
(Fig. 4).
Bone is themain site of metastasis for prostate cancer cells, which
depend on bone-derived factors for their drug resistance. Indeed, the
culture medium from either primary osteoblast-like cells or from the
MC3T3 cell line can stimulate proliferation of prostate cancer cell
lines in a sphingosine 1-phosphate (S1P)-dependent manner [98].
S1P, a bioactive lipid mediator, is an important component of various
processes in cancer biology, including cell proliferation, differentia-
tion and survival. These effects are transmitted mainly through its
ﬁve high-afﬁnity surface G-protein-coupled receptors S1P1–5. One
study noted that the culture medium from MC3T3 cells enhanced
the survival of CaP cells treated with docetaxel (a cytotoxicFig. 4. Stromal cell-derived G-CSF contributes to acute myeloid leukemia drug resistance. Whe
AML cells continue to proliferate in the presence a c-KIT/ABL inhibitor. This protection is confechemotherapy drug of the taxane family) or gamma-irradiation. These
proliferative and survival effects were abolished when S1P secretion
or activity from osteoblastic cells was blocked. This established that
osteoblast-derived S1P can act as a paracrine survival factor and confer
resistance to therapeutics against bone metastasis-derived prostate
cancer [98].5. Cytokines can be predictive biomarkers in cancer drug treatment
Sunitinib (known as Sutent by Pﬁzer), a broad spectrum TKI, is FDA-
approved for the treatment of metastatic renal-cell carcinoma (MRCC).
Research endeavors have focused on identifying predictive markers of
sunitinib activity inMRCC. To this end, a cytokine antibody array detect-
ing 174 human cytokines was employed to screen serum samples from
31 MRCC patients treated with sunitinib. In MRCC patients that did not
respond to sunitinib, TNF-alpha and MMP-9 baseline levels were found
to be signiﬁcantly increased, and signiﬁcantly associated with reduced
overall survival and time-to-progression, concluding that levels of
these two cytokines may be predictive markers of sunitinib activity in
MRCC [99]. Because many patients develop sunitinib resistance and
progressive disease after about 1 year of treatment, other studies have
focused on the mechanisms of resistance. To this end, xenografts were
developed to model clinical presentation. In this system, sunitinib-
resistant tumors were found to exhibit increased secretion of IL-8 and
higher microvessel density, while neutralization of IL-8 resensitized
the tumor to sunitinib. Thus, IL-8 is both an important marker of suniti-
nib resistance and a candidate therapeutic target to reverse it [100]. In
further attempts to identify factors that might predict response to suni-
tinib in MRCC, serum VEGF and neutrophil gelatinase-associated
lipocalin (NGAL) levels were determined in 85 patients. Both VEGF
and NGAL levels in serum proved accurate predictors of progression-
free survival, and thus represent candidate biomarkers of the efﬁcacy
of sunitinib in MRCC patients [101].
In a study of clinical patients with pancreatic cancer treated with
gemcitabine (a nucleoside analog), patients with both high serum IL-6
and IL-1 beta levels exhibited shortened overall and progression-free
survival and a reduction in the tumor control rate. Together, serum
levels of IL-6 and IL-1 beta can predict the efﬁcacy of gemcitabine in pa-
tients with advanced pancreatic cancer [102].n in co-culture with HS-5 stromal cells or grown in conditioned medium from HS-5 cells,
rred by high levels of G-CSF secreted from stromal cells.
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Resistance to chemotherapy and oncoprotein-targeted drugs re-
mains the biggest impediment in oncology, disrupting the long term
success of treatment of cancer patients. In this review, we described
and assessed examples of the mechanisms by which cells and tissues
develop resistance against chemotherapy drugs, particularly those in-
volving altered cytokine expression and their downstream signaling
networks. As mentioned earlier, our understanding of the molecular
mechanisms of chemoresistance iswoefully incomplete. The studies de-
scribed here however, have contributed foundational insights, identify-
ing several key pathwayswhich cancer cells commonly hyperactivate or
block in order to evade targeted therapeutic agents. These pathway per-
turbations are caused by (or result in) a telltale cytokine signature. Indi-
vidually, these cytokines can stimulate tumor-promoting pathways
through autocrine loops and/or paracrine mechanisms emanating
from re-educated stromal cells. Collectively, these cytokines contribute
to a TME which is permissive to tumor progression and drug resistance
(Table 1).
Perhaps the most habitual mediator of resistance mechanisms is IL-
6. IL-6 is in fact, one of the most universally dysregrulated cytokines in
cancer patients [103]. The relevance of this cytokine as a prognostic
biomarker was initially noted in breast and prostate cancers, where el-
evated serum levels correlated with advanced stage disease and poor
prognosis. A pleiotropic cytokine with a variety of biological activities
in inﬂammation, hematopoiesis, and immune regulation, IL-6 is
expressed by many cell types. The pleiotropy and redundant functions
of IL-6 are attributable to its bifunctional receptor system, which con-
sists of the IL-6 receptor (the IL-6-speciﬁc component) and the common
signaling receptor gp130. The dimerization of these 2 components re-
sults in activation of the JAK–STAT, Akt, and Ras–MAPK pathways
[104]. At present, the involvement of the IL-6/IL-6R signaling axis in on-
cogenic transformations is well established.
The IL-6 gene has a promoter region containing an NF-kappa B-
binding site [105]. NF-kappa B, a master orchestrator of inﬂammationTable 1
Cytokines and their proposed roles in drug resistance.
Cancer type Drug Drug target Cy
Prostate Enzalutamide Androgen receptor IL-
Prostate Etoposide Topoisomerase II Ad
Breast Doxorubicin Topoisomerase II IL-
Breast
Paclitaxel,
Doxorubicin
Microtubule function; topoisomerase II IL-
Breast Tamoxifen Estrogen receptor RA
Breast Trastuzumab HER2/neu Am
Thyroid
Cisplatinum,
Doxorubicin, Taxol
DNA replication & repair; microtubule
function; topoisomerase II
IL-
Fibrosarcoma Mitomycine C DNA replication & repair
Au
mo
Lung Geﬁtinib EGFR HG
Lung Erlotinib EGFR IL-
Lung
Dacomitinib
(PF-00299804)
EGFR HG
Melanoma PLX4720 B-RAF HG
Melanoma Vemurafenib B-RAF
IGF
PD
Pancreatic Gemcitabine DNA replication & repair SD
Chronic myeloid
leukemia
Imatinib, Nilotinib,
Dasatinib
BCR-ABL kinase/c-KIT
IL-
GM
Acute myeloid
leukemia
Imatinib, Nilotinib BCR-ABL kinase/c-KIT G-C
Renal cell carcinoma Sunitinib Tyrosine kinase VE
Renal cell carcinoma Sunitinib Tyrosine kinase
TN
MM
Renal cell carcinoma Sunitinib Tyrosine kinase IL-
Other RO4929097 Gamma-secretase IL-and innate immunity, has recently emerged as a crucial component of
oncogenesis and tumor progression [106]. NF-kappa B regulates many
of the cellular processes which, when dysregulated, become the hall-
marks of cancer; these include proliferation, cell adhesion, pro-
survival programs, and secretion of a plethora of cytokines whichmod-
ulate immune response and inﬂuence themicroenvironment. The same
can be said of STAT3, a rapidly inducible transcription factor which
controls a broad array of cellular defense responses, and which is
often inappropriately activated in tumor cells. It is now apparent that
constitutive activation of either NF-kappa B or STAT3 (or both) typiﬁes
many cancer types. The dysregulation of these pathwaysmay arise from
sustained exposure of the cell to paracrine cytokines or frommutations
in upstream signalingmolecules that result in pathway hyperactivation
within the cell [106–108]. The end result is the release of key cytokines
which create a microenvironment that is hypervascularized and replete
with immunosuppressive stromal cells.
HGF and its cognate receptor MET have emerged as lynchpin
markers in certain melanomas and NSCLCs. Oncogenesis has been doc-
umented as a result of either overexpression of HGF (which activates
MET in an autocrine fashion) or overexpression of MET itself [83,109].
This then leads to dysregulated signaling through the RAS/RAF/MEK/
ERK axis, which stimulates abnormal proliferation.
There ismounting evidence for the emergence of compensatory path-
way activation by tumor cells to escape the effects of oncoprotein-
targeted drugs. For example, lung adenocarcinoma cells can bypass
geﬁtinib-mediated ErbB3 blockade by autocrine upregulation of HGF,
which in turn stimulates the PI3-kinase/Akt pathway downstream of
MET [72,109]. HGFwas also identiﬁed as a stroma-derived paracrineme-
diator of RAF inhibitor resistance in B-RAF mutant melanoma, and this
protection proceeds through ERK and Akt pathway activation [83].
These alternate pathwaysmay represent an important Achilles heel in re-
sistant cancer cells, as suggested by the observation that STAT3 knock-
down resensitizes EGFRmutant PC-9 cells to erlotinib [69]. It should be
noted that in the studies mentioned above, the identiﬁcation of alternate
cancer-sustaining pathways was enabled by the screening of secretedtokine Cytokine function(s) Ref #
6 Blocks enzalutamide apoptosis via STAT3 [53]
renomedullin Reduces ERK1/2 phosphorylation and PARP cleavage [66]
6 Induces upregulation of mdr-1 [50]
6, IL-8 Associatedwith P-gp expression; required forMDR phenotype [54]
NTES Induces phosphorylation of STAT3 (Tyr705) [70]
phiregulin
Associated with poor response to trastuzumab, possibly
through increased AKT and ERK signaling
[76]
4, IL-10 Upregulates Bcl-2 and Bcl-xL; blocks apoptosis [68]
tocrine
tility factor
Blocks expression of Apaf-1 and caspase-9 [65]
F Restores P13-kinase signaling through MET activation [72]
6, IL-1 alpha Feedback activation of STAT3 and IRF1 through IL-6/JAK1 [69]
F
Accelerates development ofMET ampliﬁcation, which then
restores Akt signaling
[73]
F
Stromally-derived HGF activates MAPK and Akt signaling
through MET
[83]
-1, EGF,
GFD, others
Hyperactivation of PI3 kinase/Akt signaling [71]
F-1 alpha
Stromally-derived SDF-1 alpha activates FAK/Akt & ERK1/2
signaling in a CXCR4-dependent manner
[91]
6, G-CSF,
-CSF
Stromally-derived cytokines putatively activate JAK2 signaling [94]
SF Attenuates apoptosis [97]
GF, NGAL Predicts PFS [101]
F alpha,
P-9
Associated with reduced overall survival and
time-to-progression
[99]
8 Associated with resistance [100]
6, IL-8 Restores angiogenesis [55]
263V.S. Jones et al. / Biochimica et Biophysica Acta 1865 (2016) 255–265factors or receptor activation using antibody array technology. It is thus
expected that the approach of collecting broad protein signatures of
both cancerous and stromal cells will reveal a wealth of information
about the biology of the TME and its enigmatic role in chemoresistance.
In fact, Straussman et al. noted that the HGF-mediated resistance to RAF
inhibition which they reported was but one of the scores of drug resis-
tance interactions identiﬁed in their screen [83].
The combination ofmany recent insights into the signalingnetworks
of chemoresistance are repeatedly converging on the idea that drug re-
sistance may be circumvented by using treatment regimens employing
combinations of precisely targeted inhibitors, provided the tumor can
be sufﬁciently characterized ﬁrst. In fact, a number of combination
targeted therapies have been investigated both clinically and preclini-
cally, with the idea that coinhibition of 2 or more important compensa-
tory signaling pathways can block the tumor's potential escape route.
However, targeted combination therapies are still in very early stages
of development and only a few clinical successes have been achieved
(notably, dual inhibition of HER2 and mTOR pathways) [110]. But how
should we approach characterizing tumor cells and prescreening pa-
tients to prescribe the optimal combination of drugs? Recent advances
have equipped scientists with many investigative tools to identify the
prominent adaptive and microenvironmental changes that underlie re-
sistance against therapies. Identifying the cobweb of cellular modiﬁca-
tions even in the context of one drug and one cancer type is an
arduous task, as is evident by themultitude of researchmanuscripts de-
voted to this topic. For example, open ended screens that employ short
guide RNAs that activate CRISPR/Cas9-based gene knockouts, identiﬁed
constitutively expressed genes that drive resistance [111,112]. Other
cell culture-based screening approaches in combination with antibody
array-based expression proﬁling identiﬁed proteins that function inmi-
croenvironmental induced drug resistance [83]. Extensive drug-based
screening discovered mechanisms of resistance using pharmacologic
probes that block resistance [113]. Indeed, speciﬁcmechanisms of resis-
tance were discovered in individual tumors by taking biopsy samples
from EGFR mutation-positive lung adenocarcinoma patients. Cell lines
established from these biopsies were subjected to drug screens, where-
upon potential chemotherapeutic drugs that increased the sensitivity of
patient-derived cancer cells were discovered [95]. Together, it is expect-
ed that approaches like these will progress and become more sophisti-
cated in their approach to study drug resistance.
Using these reports as rationale, we have shown that multiplex im-
munoassays which can quickly collect inﬂammatory, angiogenic, apo-
ptotic, or growth factor proﬁles, identify prognostic biomarkers and
reveal critical but unexpected pathway activation in multiple cell
types. Due to the heterogeneity of tumor cell populations and of differ-
ent cancer types, the idea of commonmechanisms seems to now be ob-
solete. Likewise, the idea of a single protein as a cancer biomarker is of
little use, as it is now apparent that panels of multiple cytokines are
more informative as prognostic measures of cancer [114].
The last decade has brought an explosive growth in our understand-
ing of how tumors evade and usurp the immune system, andwith it, the
much anticipated realization of cancer immunotherapy. This novel
treatmentmodality refers to agents which exploit and augment the im-
mune system's intrinsic ability to target speciﬁcmutations expressed by
cancers. Employing the strategy of immune checkpoint therapy has
given us three breakthrough agents: a monoclonal antibody against cy-
totoxic T-lymphocyte-associated protein 4 (CTLA-4) (ipilimumab) and
two monoclonal antibodies against programmed death-1 (PD-1)
(pembrolizumab and nivolumab) for the treatment of advanced mela-
noma. Another immunotherapy strategy which is currently on an up-
ward trajectory is chimeric antigen receptors (CAR; composed of a
single chain antibody fused to intracellular signaling chains) T cell adop-
tive immunotherapy. In the wake of the successes of anti-CTLA-1 and
anti-PD-1, the biggest obstacle to further advancement of cancer immu-
notherapy is the identiﬁcation of more target molecules which are can-
cer cell-speciﬁc.Enhanced knowledge of oncogene signaling pathways and networks
will undoubtedly advance chemotherapeutic procedures by determin-
ing the best consolidations of drugs to employ. This knowledge is gath-
ered frommeasuring both the intrinsic protein signaturewithin tumors,
and the protein signature of circulating blood. With the increased
knowledge of the cytokine proﬁles that deﬁnes cancer resistance, we
expect to see longer-term remissions in the future.
Statement of conﬂict of interest
All of the authors of this paper are employees of RayBiotech, Inc., a
company producing commercial antibody arrays which were used in
some cited references.
Acknowledgments
Wewould like to express our thanks to the following for the support
of RayBiotech: The Innovative Research Fund, Guangdong innovative
research team program (201001s0104659419), Foundation of Enter-
prise University Research Institute Cooperation of Guangdong Province
andMinistry of Educationof China (2012B090600021), Special program
for the development of technology business incubators in Guangzhou
(2013J4200016), Foundation of Enterprise University Research Institute
Cooperation of Guangdong Province andMinistry of Education of China
(2012B091000145), National High Technology Research and Develop-
ment Program 863 (2014AA020905), ‘Five-twelfth’ National Science
and Technology Support Program (2012EP001000), UK-China (Guang-
zhou) Healthtech Open Innovation (2014Q-P037), and the Guangdong
Provincial Science and Technology SME Technology Innovation Fund
Program (2015A010101492).
References
[1] E. Frei III, et al., The effectiveness of combinations of antileukemic agents in induc-
ing and maintaining remission in children with acute leukemia, Blood 26 (5)
(1965) 642–656.
[2] E. Frei III, E.J. Freireich, Progress and perspectives in the chemotherapy of acute leu-
kemia, Adv. Chemother. 2 (1965) 269–298.
[3] D.A. Haber, N.S. Gray, J. Baselga, The evolving war on cancer, Cell 145 (1) (2011)
19–24.
[4] H. Zahreddine, K.L. Borden, Mechanisms and insights into drug resistance in can-
cer, Front. Pharmacol. 4 (2013) 28.
[5] C. Holohan, et al., Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer
13 (10) (2013) 714–726.
[6] M.M. Gottesman, Mechanisms of cancer drug resistance, Annu. Rev. Med. 53
(2002) 615–627.
[7] J. Bai, et al., Predominant Bcl-XL knockdown disables antiapoptotic mechanisms:
tumor necrosis factor-related apoptosis-inducing ligand-based triple chemothera-
py overcomes chemoresistance in pancreatic cancer cells in vitro, Cancer Res. 65
(6) (2005) 2344–2352.
[8] G. Wang, et al., Quercetin potentiates doxorubicin mediated antitumor effects
against liver cancer through p53/Bcl-xl, PLoS One 7 (12) (2012), e51764.
[9] E.L. Niero, et al., The multiple facets of drug resistance: one history, different ap-
proaches, J. Exp. Clin. Cancer Res. 33 (2014) 37.
[10] E.A. Ho, M. Piquette-Miller, Regulation of multidrug resistance by pro-
inﬂammatory cytokines, Curr. Cancer Drug Targets 6 (4) (2006) 295–311.
[11] G.K. Hansson, Inﬂammation, atherosclerosis, and coronary artery disease, N. Engl. J.
Med. 352 (16) (2005) 1685–1695.
[12] B. Moser, et al., Chemokines: multiple levels of leukocytemigration control, Trends
Immunol. 25 (2) (2004) 75–84.
[13] J.A. Belperio, et al., CXC chemokines in angiogenesis, J. Leukoc. Biol. 68 (1) (2000)
1–8.
[14] K.A. Janes, et al., A systems model of signaling identiﬁes a molecular basis set for
cytokine-induced apoptosis, Science 310 (5754) (2005) 1646–1653.
[15] K.E. de Visser, J. Jonkers, Towards understanding the role of cancer-associated in-
ﬂammation in chemoresistance, Curr. Pharm. Des. 15 (16) (2009) 1844–1853.
[16] D.W. McMillin, J.M. Negri, C.S. Mitsiades, The role of tumour–stromal interactions
in modifying drug response: challenges and opportunities, Nat. Rev. Drug Discov.
12 (3) (2013) 217–228.
[17] J.J. Wilson, et al., Antibody arrays in biomarker discovery, Adv. Clin. Chem. 69
(2015) 255–324.
[18] B. Burkholder, et al., Tumor-induced perturbations of cytokines and immune cell
networks, Biochim. Biophys. Acta 1845 (2) (2014) 182–201.
[19] B.B. Ruo-Pan Huang, Valerie Sloane Jones, Wei-Dong Jiang, Ying-Qing Mao, Qiao-
Lin Chen, Zhi Shi, Cytokine antibody arrays in biomarker discovery and validation,
Curr. Proteomics 9 (1) (2012) 55–70.
264 V.S. Jones et al. / Biochimica et Biophysica Acta 1865 (2016) 255–265[20] J.J. Wilson, et al., Antibody Arrays in Biomarker DiscoveryAdv Clin Chem 2015.
[21] H.L. Goel, A.M. Mercurio, VEGF targets the tumour cell, Nat. Rev. Cancer 13 (12)
(2013) 871–882.
[22] M.J. Waldner, M.F. Neurath, Targeting the VEGF signaling pathway in cancer ther-
apy, Expert Opin. Ther. Targets 16 (1) (2012) 5–13.
[23] M. Etscheid, et al., Inhibition of bFGF/EGF-dependent endothelial cell proliferation
by the hyaluronan-binding protease from human plasma, Eur. J. Cell Biol. 82 (12)
(2004) 597–604.
[24] X. Xin, et al., Hepatocyte growth factor enhances vascular endothelial growth
factor-induced angiogenesis in vitro and in vivo, Am. J. Pathol. 158 (3) (2001)
1111–1120.
[25] G. Seghezzi, et al., Fibroblast growth factor-2 (FGF-2) induces vascular endothelial
growth factor (VEGF) expression in the endothelial cells of forming capillaries: an
autocrine mechanism contributing to angiogenesis, J. Cell Biol. 141 (7) (1998)
1659–1673.
[26] C. Basilico, D. Moscatelli, The FGF family of growth factors and oncogenes, Adv.
Cancer Res. 59 (1992) 115–165.
[27] H. Ikushima, K. Miyazono, TGFbeta signalling: a complex web in cancer progres-
sion, Nat. Rev. Cancer 10 (6) (2010) 415–424.
[28] C.D. Morrison, J.G. Parvani, W.P. Schiemann, The relevance of the TGF-beta Paradox
to EMT-MET programs, Cancer Lett. 341 (1) (2013) 30–40.
[29] G. Shay, C.C. Lynch, B. Fingleton, Moving targets: emerging roles for MMPs in can-
cer progression and metastasis, Matrix Biol. 44-46 (2015) 200–206.
[30] M.B. Nilsson, R.R. Langley, I.J. Fidler, Interleukin-6, secreted by human ovarian car-
cinoma cells, is a potent proangiogenic cytokine, Cancer Res. 65 (23) (2005)
10794–10800.
[31] B. Dankbar, et al., Vascular endothelial growth factor and interleukin-6 in paracrine
tumor-stromal cell interactions in multiple myeloma, Blood 95 (8) (2000)
2630–2636.
[32] C. Ravoet, et al., Tumour stimulating effects of recombinant human interleukin-6,
Lancet 344 (8936) (1994) 1576–1577.
[33] R. Salgado, et al., Circulating interleukin-6 predicts survival in patients with meta-
static breast cancer, Int. J. Cancer 103 (5) (2003) 642–646.
[34] M. Bar-Eli, Role of interleukin-8 in tumor growth and metastasis of human mela-
noma, Pathobiology 67 (1) (1999) 12–18.
[35] S. Huang, et al., Level of interleukin-8 expression by metastatic human melanoma
cells directly correlates with constitutive NF-kappaB activity, Cytokines Cell Mol.
Ther. 6 (1) (2000) 9–17.
[36] L. Xu, I.J. Fidler, Interleukin 8: an autocrine growth factor for human ovarian cancer,
Oncol. Res. 12 (2) (2000) 97–106.
[37] R.M. Strieter, et al., Cancer CXC chemokine networks and tumour angiogenesis,
Eur. J. Cancer 42 (6) (2006) 768–778.
[38] A. Ben-Baruch, Themultifaceted roles of chemokines inmalignancy, Cancer Metas-
tasis Rev. 25 (3) (2006) 357–371.
[39] E. Azenshtein, et al., The CC chemokine RANTES in breast carcinoma progression:
regulation of expression and potential mechanisms of promalignant activity, Can-
cer Res. 62 (4) (2002) 1093–1102.
[40] R. Salcedo, et al., Human endothelial cells express CCR2 and respond to MCP-1: di-
rect role of MCP-1 in angiogenesis and tumor progression, Blood 96 (1) (2000)
34–40.
[41] M.H. Mannino, et al., The paradoxical role of IL-10 in immunity and cancer, Cancer
Lett. 367 (2) (2015) 103–107.
[42] I.H. Benoy, et al., Increased serum interleukin-8 in patients with early and metasta-
tic breast cancer correlates with early dissemination and survival, Clin. Cancer Res.
10 (21) (2004) 7157–7162.
[43] J.S. Berek, et al., Serum interleukin-6 levels correlate with disease status in patients
with epithelial ovarian cancer, Am. J. Obstet. Gynecol. 164 (4) (1991) 1038–1042
discussion 1042-3.
[44] G.P. Schneider, et al., The diverse role of chemokines in tumor progression: pros-
pects for intervention (Review), Int. J. Mol. Med. 8 (3) (2001) 235–244.
[45] M. García-Carrasco, et al., P-glycoprotein in autoimmune rheumatic diseases,
Autoimmun. Rev. 14 (7) (2015) 594–600.
[46] A. Breier, et al., New insight into p-glycoprotein as a drug target, Anti Cancer
Agents Med. Chem. 13 (1) (2013) 159–170.
[47] H. Sui, Z.Z. Fan, Q. Li, Signal transduction pathways and transcriptional mechanisms
of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells, J. Int. Med.
Res. 40 (2) (2012) 426–435.
[48] H. Knüpfer, R. Preiß, Signiﬁcance of interleukin-6 (IL-6) in breast cancer (review),
Breast Cancer Res. Treat. 102 (2) (2007) 129–135.
[49] G. Zhang, I. Adachi, Serum interleukin-6 levels correlate to tumor progression and
prognosis in metastatic breast carcinoma, Anticancer Res. 19 (2) (1999)
1427–1432.
[50] D. Conze, et al., Autocrine production of interleukin 6 causes multidrug resistance
in breast cancer cells, Cancer Res. 61 (24) (2001) 8851–8858.
[51] M. van Gameren, et al., Effects of recombinant human interleukin-6 in cancer pa-
tients: a phase I–II study, Blood 84 (5) (1994) 1434.
[52] I.T. Cavarretta, et al., The antiapoptotic effect of IL-6 autocrine loop in a cellular
model of advanced prostate cancer is mediated by Mcl-1, Oncogene 26 (20)
(2007) 2822–2832.
[53] C. Liu, et al., Inhibition of constitutively active Stat3 reverses enzalutamide resis-
tance in LNCaP derivative prostate cancer cells, Prostate 74 (2) (2014) 201–209.
[54] Z. Shi, et al., Enhanced chemosensitization in multidrug-resistant human breast
cancer cells by inhibition of IL-6 and IL-8 production, Breast Cancer Res. Treat.
135 (3) (2012) 737–747.
[55] W. He, et al., High tumor levels of IL6 and IL8 abrogate preclinical efﬁcacy of the
gamma-secretase inhibitor, RO4929097, Mol. Oncol. 5 (3) (2011) 292–301.[56] C. Nakanishi, M. Toi, Nuclear factor-κB inhibitors as sensitizers to anticancer drugs,
Nat. Rev. Cancer 5 (4) (2005) 297–309.
[57] F. Li, G. Sethi, Targeting transcription factor NF-κB to overcome chemoresistance
and radioresistance in cancer therapy, Biochim. Biophys. Acta 1805 (2) (2010)
167–180.
[58] M. Chaturvedi, et al., NF-κB addiction and its role in cancer: ‘one size does not ﬁt
all’, Oncogene 30 (14) (2011) 1615–1630.
[59] S.A. Vlahopoulos, et al., Dynamic aberrant NF-κB spurs tumorigenesis: a new
model encompassing the microenvironment, Cytokine Growth Factor Rev. 26 (4)
(2015) 389–403.
[60] Y. Ben-Neriah, M. Karin, Inﬂammation meets cancer, with NF-[kappa] B as the
matchmaker, Nat. Immunol. 12 (8) (2011) 715–723.
[61] J.A. DiDonato, F. Mercurio, M. Karin, NF-κB and the link between inﬂammation and
cancer, Immunol. Rev. 246 (1) (2012) 379–400.
[62] T. Hideshima, et al., Bortezomib induces canonical nuclear factor-κB activation in
multiple myeloma cells, Blood 114 (5) (2009) 1046–1052.
[63] C. Li, et al., Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent
IκBα degradation, J. Biol. Chem. 285 (21) (2010) 16096–16104.
[64] B. Singha, et al., Proteasome inhibition increases recruitment of IκB kinase β
(IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter,
resulting in increased IL-8 production in ovarian cancer cells, J. Biol. Chem. 289 (5)
(2014) 2687–2700.
[65] A. Haga, et al., Autocrine motility factor signaling induces tumor apoptotic resis-
tance by regulations Apaf-1 and Caspase-9 apoptosome expression, Int. J. Cancer
107 (5) (2003) 707–714.
[66] I. Abasolo, L.M. Montuenga, A. Calvo, Adrenomedullin prevents apoptosis in pros-
tate cancer cells, Regul. Pept. 133 (1–3) (2006) 115–122.
[67] I. Abasolo, et al., Adrenomedullin inhibits prostate cancer cell proliferation through
a cAMP-independent autocrine mechanism, Biochem. Biophys. Res. Commun. 322
(3) (2004) 878–886.
[68] G. Stassi, et al., Thyroid cancer resistance to chemotherapeutic drugs via autocrine
production of interleukin-4 and interleukin-10, Cancer Res. 63 (20) (2003)
6784–6790.
[69] H.J. Lee, et al., Drug resistance via feedback activation of Stat3 in oncogene-
addicted cancer cells, Cancer Cell 26 (2) (2014) 207–221.
[70] E.H. Yi, et al., STAT3-RANTES autocrine signaling is essential for tamoxifen resis-
tance in human breast cancer cells, Mol. Cancer Res. 11 (1) (2013) 31–42.
[71] A.C. Obenauf, et al., Therapy-induced Tumour Secretomes Promote Resistance and
Tumour ProgressionNature 2015.
[72] S. Yano, et al., Hepatocyte growth factor induces geﬁtinib resistance of lung adeno-
carcinoma with epidermal growth factor receptor-activating mutations, Cancer
Res. 68 (22) (2008) 9479–9487.
[73] A.B. Turke, et al., Preexistence and clonal selection of MET ampliﬁcation in EGFR
mutant NSCLC, Cancer Cell 17 (1) (2010) 77–88.
[74] R. Lupu, R.B. Dickson, M.E. Lippman, The role of erbB-2 and its ligands in growth
control of malignant breast epithelium, J. Steroid Biochem. Mol. Biol. 43 (1–3)
(1992) 229–236.
[75] D. Graus-Porta, et al., ErbB-2, the preferred heterodimerization partner of all ErbB
receptors, is a mediator of lateral signaling, EMBO J 16 (7) (1997) 1647–1655.
[76] J.W. Kim, et al., Amphiregulin Confers Trastuzumab Resistance Via AKT and ERK
Activation in HER2-positive Breast CancerJ Cancer Res Clin Oncol 2015.
[77] S.J. Turley, V. Cremasco, J.L. Astarita, Immunological hallmarks of stromal cells in
the tumour microenvironment, Nat. Rev. Immunol. 15 (11) (2015) 669–682.
[78] D.F. Quail, J.A. Joyce, Microenvironmental regulation of tumor progression andme-
tastasis, Nat. Med. 19 (11) (2013) 1423–1437.
[79] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144 (5)
(2011) 646–674.
[80] N.A. Bhowmick, E.G. Neilson, H.L. Moses, Stromal ﬁbroblasts in cancer initiation
and progression, Nature 432 (7015) (2004) 332–337.
[81] L.M. Coussens, Z. Werb, Inﬂammation and cancer, Nature 420 (6917) (2002)
860–867.
[82] A. Abramsson, P. Lindblom, C. Betsholtz, Endothelial and nonendothelial sources of
PDGF-B regulate pericyte recruitment and inﬂuence vascular pattern formation in
tumors, J. Clin. Invest. 112 (8) (2003) 1142–1151.
[83] R. Straussman, et al., Tumour micro-environment elicits innate resistance to RAF
inhibitors through HGF secretion, Nature 487 (7408) (2012) 500–504.
[84] M.V. Apte, et al., Desmoplastic reaction in pancreatic cancer: role of pancreatic stel-
late cells, Pancreas 29 (3) (2004) 179–187.
[85] W. Huanwen, et al., Intrinsic chemoresistance to gemcitabine is associated with
constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer
cell lines, Mol. Cancer 8 (2009) 125.
[86] J. Guan, et al., Retinoic acid inhibits pancreatic cancer cell migration and EMT
through the downregulation of IL-6 in cancer associated ﬁbroblast cells, Cancer
Lett. 345 (1) (2014) 132–139.
[87] E. Bertran, et al., Overactivation of the TGF-beta pathway confers a mesenchymal-
like phenotype and CXCR4-dependent migratory properties to liver tumor cells,
Hepatology 58 (6) (2013) 2032–2044.
[88] M.K. Conley-LaComb, et al., PTEN loss mediated Akt activation promotes prostate
tumor growth and metastasis via CXCL12/CXCR4 signaling, Mol. Cancer 12 (1)
(2013) 85.
[89] Y.H. Choi, et al., CXCR4, but not CXCR7, discriminates metastatic behavior in non-
small cell lung cancer cells, Mol. Cancer Res. 12 (1) (2014) 38–47.
[90] B.C. Lee, et al., Involvement of the chemokine receptor CXCR4 and its ligand
stromal cell-derived factor 1alpha in breast cancer cell migration through
human brain microvascular endothelial cells, Mol. Cancer Res. 2 (6) (2004)
327–338.
265V.S. Jones et al. / Biochimica et Biophysica Acta 1865 (2016) 255–265[91] H. Zhang, et al., Paracrine SDF-1alpha Signaling Mediates the Effects of PSCs on
GEM Chemoresistance Through an IL-6 Autocrine Loop in Pancreatic Cancer
CellsOncotarget 2014.
[92] S. Manier, et al., Bone marrow microenvironment in multiple myeloma progres-
sion, J. Biomed. Biotechnol. 2012 (2012) 157496.
[93] X. Li, et al., Bone marrow microenvironment confers imatinib resistance to chronic
myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3
pathway, Arch. Toxicol. 89 (1) (2015) 121–136.
[94] E. Traer, et al., Blockade of JAK2-mediated extrinsic survival signals restores sensi-
tivity of CML cells to ABL inhibitors, Leukemia 26 (5) (2012) 1140–1143.
[95] P. Gallipoli, et al., JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to
the elimination of CML CD34+ cells in vitro and in vivo, Blood 124 (9) (2014)
1492–1501.
[96] Y. Tabe, M. Konopleva, Advances in understanding the leukaemia microenviron-
ment, Br. J. Haematol. 164 (6) (2014) 767–778.
[97] P.M. Gordon, S. Dias, D.A. Williams, Cytokines secreted by bone marrow stromal
cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis, Leu-
kemia 28 (11) (2014) 2257–2260.
[98] L. Brizuela, et al., Osteoblast-derived sphingosine 1-phosphate to induce prolifera-
tion and confer resistance to therapeutics to bonemetastasis-derived prostate can-
cer cells, Mol. Oncol. 8 (7) (2014) 1181–1195.
[99] J.L. Perez-Gracia, et al., Identiﬁcation of TNF-alpha andMMP-9 as potential baseline
predictive serummarkers of sunitinib activity in patients with renal cell carcinoma
using a human cytokine array, Br. J. Cancer 101 (11) (2009) 1876–1883.
[100] D. Huang, et al., Interleukin-8mediates resistance to antiangiogenic agent sunitinib
in renal cell carcinoma, Cancer Res. 70 (3) (2010) 1063–1071.
[101] C. Porta, et al., Predictive value of baseline serum vascular endothelial growth fac-
tor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer pa-
tients receiving sunitinib, Kidney Int. 77 (9) (2010) 809–815.[102] S. Mitsunaga, et al., Serum levels of IL-6 and IL-1beta can predict the efﬁcacy of
gemcitabine in patients with advanced pancreatic cancer, Br. J. Cancer 108 (10)
(2013) 2063–2069.
[103] B. Seruga, et al., Cytokines and their relationship to the symptoms and outcome of
cancer, Nat. Rev. Cancer 8 (11) (2008) 887–899.
[104] T. Kishimoto, IL-6: from its discovery to clinical applications, Int. Immunol. 22 (5)
(2010) 347–352.
[105] T. Matsusaka, et al., Transcription factors NF-IL6 and NF-kappa B synergistically ac-
tivate transcription of the inﬂammatory cytokines, interleukin 6 and interleukin 8,
Proc. Natl. Acad. Sci. 90 (21) (1993) 10193–10197.
[106] N.D. Perkins, The diverse and complex roles of NF-κB subunits in cancer, Nat. Rev.
Cancer 12 (2) (2012) 121–132.
[107] S.I. Grivennikov, M. Karin, Dangerous liaisons: STAT3 and NF-κB collaboration and
crosstalk in cancer, Cytokine Growth Factor Rev. 21 (1) (2010) 11–19.
[108] H. Yu, M. Kortylewski, D. Pardoll, Crosstalk between cancer and immune cells: role of
STAT3 in the tumour microenvironment, Nat. Rev. Immunol. 7 (1) (2007) 41–51.
[109] J.A. Engelman, et al., MET ampliﬁcation leads to geﬁtinib resistance in lung cancer
by activating ERBB3 signaling, Science 316 (5827) (2007) 1039–1043.
[110] F. Li, C. Zhao, L. Wang, Molecular-targeted agents combination therapy for cancer:
developments and potentials, Int. J. Cancer 134 (6) (2014) 1257–1269.
[111] S. Konermann, et al., Genome-scale transcriptional activation by an engineered
CRISPR‐Cas9 complex, Nature 517 (7536) (2015) 583–588.
[112] O. Shalem, et al., Genome-scale CRISPR‐Cas9 knockout screening in human cells,
Science 343 (6166) (2014) 84–87.
[113] T. Pemovska, et al., Individualized systems medicine strategy to tailor treatments
for patients with chemorefractory acute myeloid leukemia, Cancer Discov. 3 (12)
(2013) 1416–1429.
[114] A.S. Crystal, et al., Patient-derived models of acquired resistance can identify effec-
tive drug combinations for cancer, Science 346 (6216) (2014) 1480–1486.
